{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:49:53Z","timestamp":1787618993992,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the rate of misdiagnosis of aneurysmatic pachychoroid type 1 choroidal neovascularization\/polypoidal choroidal vasculopathy (PAT1\/PCV) among cases diagnosed as non-aneurysmatic pachychoroid neovasculopathy (PNV) and to define optical coherence tomography (OCT) features facilitating their distinction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The database of the Department of Ophthalmology, Ludwig-Maximilians University Munich, was screened for patients diagnosed with PNV. Multimodal imaging was screened for the presence of choroidal neovascularization (CNV) and aneurysms\/polyps. Imaging features facilitating the diagnosis of PAT1\/PCV were analysed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 49 eyes of 44 patients with a clinical PNV diagnosis were included, of which 42 (85.7%) had PNV and 7 (14.3%) represented misdiagnosed PAT1\/PCV. SFCT was comparable (PNV: 377\u2009\u00b1\u200992 vs. PAT1\/PCV: 400\u2009\u00b1\u200983\u2009\u00b5m; <jats:italic>p<\/jats:italic>\u2009=\u20090.39). Whereas no difference was detected in total pigment epithelium detachment (PED) diameter (<jats:italic>p<\/jats:italic>\u2009=\u20090.46), maximum PED height was significantly higher in the PAT1\/PCV group (199\u2009\u00b1\u200931 vs. 82\u2009\u00b1\u200946, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001). In a receiver operating characteristic (ROC) analysis, the optimum cutoff for defining \u201cpeaking PED\u201d was 158\u2009\u00b5m with an area under the curve of 0.969, a sensitivity of 1.0 (95% CI: 0.59\u20131.0), and a specificity of 0.95 (95% CI: 0.84\u20130.99). Sub-retinal hyperreflective material (SHRM; p\u2009=\u20090.04), sub-retinal ring-like structures (SRRLS; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001), and sub-RPE fluid (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) were significantly more frequent in eyes with PAT1\/PCV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A relevant percentage of eyes diagnosed with PNV might instead suffer from PAT1\/PCV. The detection of a maximum PED height (\u201cpeaking PED\u201d) exceeding approximately 150\u2009\u00b5m, SHRM, SRRLS, and sub-RPE fluid might greatly aid in the production of a more accurate diagnosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-023-02529-5","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T14:02:57Z","timestamp":1683554577000},"page":"3435-3441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optical coherence tomography-based misdiagnosis and morphological distinction in pachychoroid neovasculopathy vs. polypoidal choroidal vasculopathy"],"prefix":"10.1038","volume":"37","author":[{"given":"Jakob","family":"Siedlecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Klaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Keidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Asani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schiefelbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Knebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Luft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried G.","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schworm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"2529_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye. 2019;33:14\u201333. https:\/\/doi.org\/10.1038\/s41433-018-0158-4.","journal-title":"Eye"},{"key":"2529_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.oret.2019.08.002","volume":"3","author":"J Siedlecki","year":"2019","unstructured":"Siedlecki J, Schworm B, Priglinger SG. The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retin. 2019;3:1013\u20135. https:\/\/doi.org\/10.1016\/j.oret.2019.08.002.","journal-title":"Ophthalmol Retin"},{"key":"2529_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/iae.0000000000000331","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35:1\u20139. https:\/\/doi.org\/10.1097\/iae.0000000000000331.","journal-title":"Retina"},{"key":"2529_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1\u20138.","journal-title":"Retina"},{"key":"2529_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/ceo.13114","volume":"46","author":"KK Dansingani","year":"2018","unstructured":"Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of \u2018expanded spectra\u2019 - a review. Clin Exp Ophthalmol. 2018;46:189\u2013200. https:\/\/doi.org\/10.1111\/ceo.13114.","journal-title":"Clin Exp Ophthalmol"},{"key":"2529_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.oret.2018.08.008","volume":"3","author":"M Li","year":"2019","unstructured":"Li M, Dolz-Marco R, Messinger JD, Sloan KR, Ferrara D, Curcio CA, et al. Clinicopathologic correlation of aneurysmal type 1 neovascularization in age-related macular degeneration. Ophthalmol Retin. 2019;3:99\u2013111. https:\/\/doi.org\/10.1016\/j.oret.2018.08.008.","journal-title":"Ophthalmol Retin"},{"key":"2529_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.04.004","author":"J Siedlecki","year":"2022","unstructured":"Siedlecki J, Klaas JE, Keidel LF, Asani B, Luft N, Priglinger SG, et al. Progression of pachychoroid neovasculopathy into aneurysmal type 1 choroidal neovascularization or polypoidal choroidal vasculopathy. Ophthalmol Retin. 2022. https:\/\/doi.org\/10.1016\/j.oret.2022.04.004.","journal-title":"Ophthalmol Retin"},{"key":"2529_CR8","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/IAE.0b013e3182680a66","volume":"32","author":"AT Fung","year":"2012","unstructured":"Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina. 2012;32:1829\u201337. https:\/\/doi.org\/10.1097\/IAE.0b013e3182680a66.","journal-title":"Retina"},{"key":"2529_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/iae.0000000000002810","volume":"41","author":"MC Savastano","year":"2021","unstructured":"Savastano MC, Rispoli M, Lumbroso B. The incidence of neovascularization in central serous chorioretinopathy by optical coherence tomography angiography. Retina. 2021;41:302\u20138. https:\/\/doi.org\/10.1097\/iae.0000000000002810.","journal-title":"Retina"},{"key":"2529_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000002662","author":"H Hwang","year":"2019","unstructured":"Hwang H, Kim JY, Kim KT, Chae JB, Kim DY. Flat irregular pigment epithelium detachment in central serous chorioretinopathy: a form of pachychoroid neovasculopathy? Retina. 2019. https:\/\/doi.org\/10.1097\/iae.0000000000002662.","journal-title":"Retina"},{"key":"2529_CR11","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1001\/jamaophthalmol.2015.2126","volume":"133","author":"SM McClintic","year":"2015","unstructured":"McClintic SM, Jia Y, Huang D, Bailey ST. Optical coherence tomographic angiography of choroidal neovascularization associated with central serous chorioretinopathy. JAMA Ophthalmol. 2015;133:1212\u20134. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.2126.","journal-title":"JAMA Ophthalmol"},{"key":"2529_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/iae.0000000000002791","volume":"41","author":"J Guo","year":"2021","unstructured":"Guo J, Tang W, Liu W, Chang Q, Xu G. Clinical features of flat irregular pigment epithelial detachment associated with choroidal neovascularization in chronic central serous chorioretinopathy. Retina. 2021;41:199\u2013207. https:\/\/doi.org\/10.1097\/iae.0000000000002791.","journal-title":"Retina"},{"key":"2529_CR13","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.4103\/ijo.IJO_377_18","volume":"66","author":"J Sheth","year":"2018","unstructured":"Sheth J, Anantharaman G, Chandra S, Sivaprasad S. \u201cDouble-layer sign\u201d on spectral domain optical coherence tomography in pachychoroid spectrum disease. Indian J Ophthalmol. 2018;66:1796\u2013801. https:\/\/doi.org\/10.4103\/ijo.IJO_377_18.","journal-title":"Indian J Ophthalmol"},{"key":"2529_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ajo.2017.03.026","volume":"178","author":"KU Kort\u00fcm","year":"2017","unstructured":"Kort\u00fcm KU, M\u00fcller M, Kern C, Babenko A, Mayer WJ, Kampik A, et al. Using Electronic Health Records to Build an Ophthalmologic Data Warehouse and Visualize Patients\u2019 Data. Am J Ophthalmol. 2017;178:84\u201393. https:\/\/doi.org\/10.1016\/j.ajo.2017.03.026.","journal-title":"Am J Ophthalmol"},{"key":"2529_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47738-9","volume":"9","author":"N Nagai","year":"2019","unstructured":"Nagai N, Suzuki M, Minami S, Kurihara T, Kamoshita M, Sonobe H, et al. Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Sci Rep. 2019;9:11389. https:\/\/doi.org\/10.1038\/s41598-019-47738-9.","journal-title":"Sci Rep."},{"key":"2529_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42052-w","volume":"9","author":"J Baek","year":"2019","unstructured":"Baek J, Kook L, Lee WK. Choriocapillaris flow impairments in association with pachyvessel in early stages of pachychoroid. Sci Rep. 2019;9:5565. https:\/\/doi.org\/10.1038\/s41598-019-42052-w.","journal-title":"Sci Rep."},{"key":"2529_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen SJ, Kim JE, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the asia-pacific ocular imaging society PCV workgroup. Ophthalmology. 2021;128:443\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.006.","journal-title":"Ophthalmology"},{"key":"2529_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125:708\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.019.","journal-title":"Ophthalmology"},{"key":"2529_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453\u201364. https:\/\/doi.org\/10.1097\/IAE.0b013e31824f91e8.","journal-title":"Retina"},{"key":"2529_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00417-020-04623-w","volume":"258","author":"B Schworm","year":"2020","unstructured":"Schworm B, Luft N, Keidel LF, Hagenau F, Kern C, Herold T, et al. Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents. Graefe\u2019s Arch Clin Exp Ophthalmol = Albrecht von Graefes Arch fur klinische und experimentelle Ophthalmologie. 2020;258:1013\u201321. https:\/\/doi.org\/10.1007\/s00417-020-04623-w.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol = Albrecht von Graefes Arch fur klinische und experimentelle Ophthalmologie"},{"key":"2529_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.32614\/RJ-2016-042","volume":"8","author":"D Goksuluk","year":"2016","unstructured":"Goksuluk D, Korkmaz S, Zararsiz G, Karaagaoglu E. easyROC: an interactive web-tool for ROC curve analysis using r language environment. R J. 2016;8:213\u201330. https:\/\/doi.org\/10.32614\/RJ-2016-042.","journal-title":"R J"},{"key":"2529_CR22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaophthalmol.2019.0565","volume":"137","author":"V Chaikitmongkol","year":"2019","unstructured":"Chaikitmongkol V, Kong J, Khunsongkiet P, Patikulsila D, Sachdeva M, Chavengsaksongkram P, et al. Sensitivity and specificity of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy. JAMA Ophthalmol. 2019;137:661\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.0565.","journal-title":"JAMA Ophthalmol"},{"key":"2529_CR23","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","volume":"33","author":"DJ Warrow","year":"2013","unstructured":"Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33:1659\u201372. https:\/\/doi.org\/10.1097\/IAE.0b013e3182953df4.","journal-title":"Retina"},{"key":"2529_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/iae.0000000000003057","volume":"41","author":"RF Spaide","year":"2021","unstructured":"Spaide RF. The ambiguity of pachychoroid. Retina. 2021;41:231\u20137. https:\/\/doi.org\/10.1097\/iae.0000000000003057.","journal-title":"Retina"},{"key":"2529_CR25","doi-asserted-by":"publisher","first-page":"e0248760","DOI":"10.1371\/journal.pone.0248760","volume":"16","author":"A Miki","year":"2021","unstructured":"Miki A, Kusuhara S, Otsuji T, Kawashima Y, Miki K, Imai H, et al. Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS ONE. 2021;16:e0248760. https:\/\/doi.org\/10.1371\/journal.pone.0248760.","journal-title":"PLoS ONE"},{"key":"2529_CR26","doi-asserted-by":"publisher","unstructured":"Tanaka, K, Mori, R, Wakatsuki, Y, Onoe, H, Kawamura, A, Nakashizuka, H. Two-thirds dose photodynamic therapy for pachychoroid neovasculopathy. J Clin Med. 10, (2021). https:\/\/doi.org\/10.3390\/jcm10102168.","DOI":"10.3390\/jcm10102168"},{"key":"2529_CR27","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00417-022-05553-5","volume":"260","author":"I Wada","year":"2022","unstructured":"Wada I, Shiose S, Ishikawa K, Kano K, Notomi S, Mori K, et al. One-year efficacy of \u201crescue photodynamic therapy\u201d for patients with typical age-related macular degeneration, polypoidal choroidal vasculopathy, and pachychoroid neovasculopathy refractory to anti-vascular endothelial growth factor therapy. Graefe\u2019s Arch Clin Exp Ophthalmol = Albrecht von Graefes Arch fur klinische und experimentelle Ophthalmologie. 2022;260:2029\u201336. https:\/\/doi.org\/10.1007\/s00417-022-05553-5.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol = Albrecht von Graefes Arch fur klinische und experimentelle Ophthalmologie"},{"key":"2529_CR28","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41433-021-01418-z","volume":"35","author":"T Hikichi","year":"2021","unstructured":"Hikichi T, Kubo N, Yamauchi M. One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. Eye. 2021;35:3367\u201375. https:\/\/doi.org\/10.1038\/s41433-021-01418-z.","journal-title":"Eye"},{"key":"2529_CR29","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138:935\u201342. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2443.","journal-title":"JAMA Ophthalmol"},{"key":"2529_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91589-2","volume":"11","author":"J Yoon","year":"2021","unstructured":"Yoon J, Yoon W, Na SK, Lee J, Kim CG, Kim JW, et al. Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. Sci Rep. 2021;11:12052. https:\/\/doi.org\/10.1038\/s41598-021-91589-2.","journal-title":"Sci Rep."},{"key":"2529_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/eye.2014.124","volume":"28","author":"HC Lin","year":"2014","unstructured":"Lin HC, Yang CH, Yang CM. Visual outcomes of vitrectomy for polypoidal choroidal vasculopathy-related breakthrough vitreous haemorrhage. Eye. 2014;28:797\u2013806. https:\/\/doi.org\/10.1038\/eye.2014.124.","journal-title":"Eye"},{"key":"2529_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73303-w","volume":"10","author":"M Tagawa","year":"2020","unstructured":"Tagawa M, Ooto S, Yamashiro K, Tamura H, Oishi A, Miyata M, et al. Characteristics of pachychoroid neovasculopathy. Sci Rep. 2020;10:16248. https:\/\/doi.org\/10.1038\/s41598-020-73303-w.","journal-title":"Sci Rep."},{"key":"2529_CR33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00417-020-04844-z","volume":"259","author":"EHC van Dijk","year":"2021","unstructured":"van Dijk EHC, Mohabati D, Veselinovic S, Chung WH, Dijkman G, Boon CJF. The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification. Graefe\u2019s Arch Clin Exp Ophthalmol = Albrecht von Graefes Arch fur klinische und experimentelle Ophthalmologie. 2021;259:351\u201361. https:\/\/doi.org\/10.1007\/s00417-020-04844-z.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol = Albrecht von Graefes Arch fur klinische und experimentelle Ophthalmologie"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02529-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T10:06:45Z","timestamp":1699351605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02529-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2529"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02529-5","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"14 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No author reports any financial interest relevant to this study. Jakob Siedlecki received previous speaker fees and travel expenses from Novartis Pharma GmbH, Carl Zeiss Meditec AG, Oculentis OSD Medical GmbH, Allergan GmbH and Heidelberg Engineering GmbH. JS received personal consultation fees from Bayer AG, Novartis Pharma GmbH, Allergan GmbH and Apellis Pharmaceuticals. BA received previous speaker fees from Novartis Pharma GmbH. LFK received income from honoraria as a lecturer from Recordati Pharma GmbH. NL received income from honoraria as a lecturer from Alcon Laboratories Inc., NIDEK Co. Ltd and CenterVue SpA. SP received previous speaker fees and\/or travel expenses from Novartis Pharma GmbH, Oertli AG, Bayer AG, Alcon Pharma GmbH and Allergan GmbH. BS received previous speaker fees and travel expenses from Novartis Pharma GmbH and Topcon Corporation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}